Skip to main content

Fangzhou Ranked among 2025 Guangzhou AI Innovation “Most Promising Enterprises” for AI‑Powered Chronic Disease Services

Written by Customer Service on . Posted in Public Companies.

GUANGZHOU, China, May 19, 2026 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, was invited to attend the 2026 Guangzhou Artificial Intelligence and Intelligent Autonomous Systems Innovation Development Promotion Conference (the “Conference”), where the Company was recognized for its technological innovation in “AI + chronic disease services.”

Fangzhou Ranked among 2025 Guangzhou AI Innovation “Most Promising Enterprises”

Fangzhou Ranked among 2025 Guangzhou AI Innovation “Most Promising Enterprises”

The Conference brought together nearly 200 representatives from government agencies, research institutions, industry leaders, and financial institutions to showcase advances in artificial intelligence and strengthen collaboration across the innovation ecosystem.

During the event, Fangzhou’s subsidiary, Guangzhou Fangzhou Information Technology Co., Ltd., was named to the “2025 Guangzhou Artificial Intelligence Innovation Development List” under the category of “Most Promising Enterprise.” This recognition marked the company’s second consecutive year on the list, following its selection in 2024, underscoring growing industry recognition of Fangzhou’s technological capabilities, service innovation, and contribution to the development of AI‑driven healthcare solutions.

Fangzhou has expanded its “AI + H2H (Hospital‑to‑Home)” smart healthcare ecosystem, leveraging AI technology to address longstanding challenges in chronic disease management. In 2026, Fangzhou further refined its strategy to position itself as a trusted long‑term health partner for chronic disease patients, with the goal of building a comprehensive care model centered on continuous care and long‑term patient engagement. Powered by its proprietary XingShi Large Language Model, the Company has integrated AI technologies across online consultation, health management, and long‑term follow‑up services, extending professional healthcare support beyond traditional clinical settings.

As artificial intelligence increasingly reshapes the healthcare industry, the Conference served as a platform to strengthen connections between innovation, industry, capital, and talent, supporting the coordinated development of the AI and healthcare industries. Fangzhou will continue strengthening its AI technology foundation, expanding the accessibility of chronic disease services through digital innovation, while helping advance the development of China’s AI healthcare sector in support of the broader Healthy China initiative.

About Fangzhou Inc.

Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 56.4 million registered users and 251,000 physicians as of December 31, 2025. The Company specializes in delivering tailored medical care and AI‑enabled precision medicine solutions. For more information, visit https://investors.jianke.com.

Media Contact

For further inquiries or interview requests, please contact:

Xingwei Zhao
Director of Public Relations
Email: pr@jianke.com

Disclaimer: This press release contains forward‑looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements, which speak only as of the date of this press release, and the Company undertakes no obligation to update them except as required by applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c2774e85-7115-4320-ad5e-ff2704381fe3

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.